BASEL, September 25, 2025 – Swiss pharmaceutical giant Roche (ROG.S) advanced its experimental obesity drug CT-388 into Phase 3 trials, targeting a top-three market position by 2030 in the rapidly growing weight-loss sector 1. The move positions Roche to challenge market leaders Eli Lilly and Novo Nordisk in a segment analysts value at over 100 billion by decade’s end.
- CT-388 moves to Phase 3 trials targeting 2026 launch
- Roche aims for top-three obesity market position by 2030
- Drug from 2.7 billion Carmot acquisition shows blockbuster potential
Market Reaction & Pipeline Strategy
Roche shares jumped nearly 5% on the announcement, reflecting investor optimism about the company’s obesity pipeline 2. The drug, acquired through Roche’s 2.7 billion purchase of Carmot Therapeutics in December 2023, represents one of six obesity compounds in the company’s development portfolio 3.
CT-388 is administered as a weekly injection and targets the same GLP-1 pathway as existing blockbuster drugs like Ozempic and Wegovy. Roche forecasts three of its obesity candidates could become blockbusters with annual sales exceeding 1 billion each 4.
Competitive Landscape
The obesity drug market is currently dominated by Eli Lilly’s Mounjaro/Zepbound and Novo Nordisk’s Ozempic/Wegovy, which have generated tens of billions in combined revenue. Roche’s entry intensifies competition in a sector experiencing unprecedented demand and supply constraints.
Early-stage trial results showed CT-388 led to significant weight loss, though specific efficacy data was not disclosed 5. The Phase 3 trials are expected to launch in 2026, with commercial availability potentially following by decade’s end.
Management Commitment
“Our goal is to become a Top 3 player in the obesity drug market, and I want you to know I’m serious about this goal,” said Teresa Graham, Roche’s head of pharmaceuticals 6.
The company’s obesity strategy builds on its established presence in diabetes and metabolic disorders. Roche has invested heavily in manufacturing capabilities and clinical infrastructure to support the anticipated scale of obesity drug production.
Market Outlook
Analysts project the global obesity drug market could reach 100 billion annually by 2030, driven by rising obesity rates and increased healthcare coverage for weight-loss treatments. The sector currently faces supply shortages as demand far exceeds manufacturing capacity across existing players.
Roche’s entry timeline suggests the company could capture meaningful market share if CT-388 demonstrates competitive efficacy and safety profiles in Phase 3 trials. The drug’s weekly dosing schedule aligns with patient preferences established by current market leaders.
Not investment advice. For informational purposes only.
References
1“Roche plans to become top 3 obesity player as CT-388 enters trial”. CNBC. Retrieved September 25, 2025.
2“Roche, muscling into weight-loss drug race, advances obesity”. Reuters. Retrieved September 25, 2025.
3“Roche unveils strategy to become ‘top 3’ obesity company”. Fierce Biotech. Retrieved September 25, 2025.
4“Roche, muscling into weight-loss drug race, advances obesity”. Yahoo Finance UK. Retrieved September 25, 2025.
5“Roche shares rise as company advances experimental obesity drug”. KFGO. Retrieved September 25, 2025.
6“Roche shares rise as experimental obesity drug moves to late-stage trial”. News.az. Retrieved September 25, 2025.